Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer

Anixa Biosciences has announced that the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for a CAR-T therapy targeting the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, has not observed any dose-limiting toxicities to date, and four patients have surpassed one year of survival following treatment. The highest dose level evaluated in the study is 1×10⁷ CAR-positive cells per kilogram of body weight. Anixa holds an exclusive license for this CAR-T technology from The Wistar Institute.